JS Link, Inc.

KOSDAQ:A127120 Stock Report

Market Cap: ₩256.0b

JS Link Past Earnings Performance

Past criteria checks 0/6

JS Link has been growing earnings at an average annual rate of 15.3%, while the Biotechs industry saw earnings growing at 17.8% annually. Revenues have been growing at an average rate of 3.9% per year.

Key information

15.3%

Earnings growth rate

27.0%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate3.9%
Return on equity-43.2%
Net Margin-67.9%
Last Earnings Update31 Dec 2024

Recent past performance updates

Recent updates

There's Reason For Concern Over DNA Link, Inc.'s (KOSDAQ:127120) Massive 29% Price Jump

Mar 26
There's Reason For Concern Over DNA Link, Inc.'s (KOSDAQ:127120) Massive 29% Price Jump

There's No Escaping DNA Link, Inc.'s (KOSDAQ:127120) Muted Revenues Despite A 27% Share Price Rise

Dec 04
There's No Escaping DNA Link, Inc.'s (KOSDAQ:127120) Muted Revenues Despite A 27% Share Price Rise

DNA Link, Inc. (KOSDAQ:127120) Shares Fly 27% But Investors Aren't Buying For Growth

Jul 12
DNA Link, Inc. (KOSDAQ:127120) Shares Fly 27% But Investors Aren't Buying For Growth

There Is A Reason DNA Link, Inc.'s (KOSDAQ:127120) Price Is Undemanding

Mar 19
There Is A Reason DNA Link, Inc.'s (KOSDAQ:127120) Price Is Undemanding

Is DNA Link (KOSDAQ:127120) Using Too Much Debt?

Apr 19
Is DNA Link (KOSDAQ:127120) Using Too Much Debt?

Introducing DNA Link (KOSDAQ:127120), A Stock That Climbed 61% In The Last Year

Feb 23
Introducing DNA Link (KOSDAQ:127120), A Stock That Climbed 61% In The Last Year

Revenue & Expenses Breakdown

How JS Link makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A127120 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2415,908-10,80210,75619
30 Sep 2419,042-11,3149,98220
30 Jun 2419,110-6,9418,75322
31 Mar 2421,046-4,2958,17019
31 Dec 2321,949-5,5968,57485
30 Sep 2318,947-6,4628,700214
30 Jun 2318,718-5,7858,49545
31 Mar 2317,427-5,6317,74166
31 Dec 2216,981-7,7827,141465
30 Sep 2219,141-7,0149,788518
30 Jun 2221,999-5,78610,207700
31 Mar 2223,186-7,52110,770792
31 Dec 2122,992-5,10010,603539
30 Sep 2119,730-9,6217,432635
30 Jun 2116,660-12,3756,862768
31 Mar 2115,903-13,1646,815660
31 Dec 2015,286-13,0676,798464
30 Sep 2015,654-14,56910,185255
30 Jun 2016,208-13,24710,376129
31 Mar 2015,333-12,61610,201354
31 Dec 1915,573-13,1189,955356
30 Sep 1914,397-5,3366,071360
30 Jun 1913,331-5,7136,071343
31 Mar 1914,300-4,9726,012120
31 Dec 1814,876-3,7536,010104
30 Sep 1814,860-2,5505,735411
30 Jun 1815,135-8635,274404
31 Mar 1814,819-234,656411
31 Dec 1714,4803384,076538
30 Sep 1714,888-2,9924,444-74
30 Jun 1714,620-5,7415,046599
31 Mar 1713,206-7,3245,016640
31 Dec 1611,484-9,8115,398585
30 Sep 1610,126-12,9385,5571,809
30 Jun 168,869-11,3414,5611,149
31 Mar 169,396-9,2834,587974
31 Dec 159,420-9,0544,1711,029
30 Sep 159,028-6,0184,20092
30 Jun 159,305-5,3214,235204
31 Dec 148,733-4,4593,412194

Quality Earnings: A127120 is currently unprofitable.

Growing Profit Margin: A127120 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A127120 is unprofitable, but has reduced losses over the past 5 years at a rate of 15.3% per year.

Accelerating Growth: Unable to compare A127120's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A127120 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (33.1%).

Return on Equity

High ROE: A127120 has a negative Return on Equity (-43.16%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/02 19:07
End of Day Share Price 2025/05/02 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

JS Link, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Al Eum LeeiM Securities
Sung Hwan ChoiKyobo Securities Co., Ltd
Kidal BaeShinhan Investment Corp.